These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 14627415

  • 1. Synthesis of migration-resistant hydroxyethoxy analogues of lysophosphatidic acid.
    Qian L, Xu Y, Arai H, Aoki J, McIntyre TM, Prestwich GD.
    Org Lett; 2003 Nov 27; 5(24):4685-8. PubMed ID: 14627415
    [Abstract] [Full Text] [Related]

  • 2. Synthesis of monofluorinated analogues of lysophosphatidic acid.
    Xu Y, Qian L, Prestwich GD.
    J Org Chem; 2003 Jun 27; 68(13):5320-30. PubMed ID: 12816494
    [Abstract] [Full Text] [Related]

  • 3. Structure-activity analysis of the effects of lysophosphatidic acid on platelet aggregation.
    Gueguen G, Gaigé B, Grévy JM, Rogalle P, Bellan J, Wilson M, Klaébé A, Pont F, Simon MF, Chap H.
    Biochemistry; 1999 Jun 29; 38(26):8440-50. PubMed ID: 10387090
    [Abstract] [Full Text] [Related]

  • 4. Structure-activity relationships of fluorinated lysophosphatidic acid analogues.
    Xu Y, Aoki J, Shimizu K, Umezu-Goto M, Hama K, Takanezawa Y, Yu S, Mills GB, Arai H, Qian L, Prestwich GD.
    J Med Chem; 2005 May 05; 48(9):3319-27. PubMed ID: 15857137
    [Abstract] [Full Text] [Related]

  • 5. Human platelets respond differentially to lysophosphatidic acids having a highly unsaturated fatty acyl group and alkyl ether-linked lysophosphatidic acids.
    Tokumura A, Sinomiya J, Kishimoto S, Tanaka T, Kogure K, Sugiura T, Satouchi K, Waku K, Fukuzawa K.
    Biochem J; 2002 Aug 01; 365(Pt 3):617-28. PubMed ID: 11982483
    [Abstract] [Full Text] [Related]

  • 6. Synthesis, pharmacology, and cell biology of sn-2-aminooxy analogues of lysophosphatidic acid.
    Gajewiak J, Tsukahara R, Fujiwara Y, Tigyi G, Prestwich GD.
    Org Lett; 2008 Mar 20; 10(6):1111-4. PubMed ID: 18284246
    [Abstract] [Full Text] [Related]

  • 7. Structure--activity relationships of lysophosphatidic acid: conformationally restricted backbone mimetics.
    Hopper DW, Ragan SP, Hooks SB, Lynch KR, Macdonald TL.
    J Med Chem; 1999 Mar 25; 42(6):963-70. PubMed ID: 10090779
    [Abstract] [Full Text] [Related]

  • 8. Enantioselective responses to a phosphorothioate analogue of lysophosphatidic acid with LPA3 receptor-selective agonist activity.
    Qian L, Xu Y, Hasegawa Y, Aoki J, Mills GB, Prestwich GD.
    J Med Chem; 2003 Dec 18; 46(26):5575-8. PubMed ID: 14667211
    [Abstract] [Full Text] [Related]

  • 9. Alkyl lysophosphatidic acid and fluoromethylene phosphonate analogs as metabolically-stabilized agonists for LPA receptors.
    Xu Y, Tanaka M, Arai H, Aoki J, Prestwich GD.
    Bioorg Med Chem Lett; 2004 Nov 01; 14(21):5323-8. PubMed ID: 15454220
    [Abstract] [Full Text] [Related]

  • 10. Lysophosphatidic acid induces human natural killer cell chemotaxis and intracellular calcium mobilization.
    Jin Y, Knudsen E, Wang L, Maghazachi AA.
    Eur J Immunol; 2003 Aug 01; 33(8):2083-9. PubMed ID: 12884281
    [Abstract] [Full Text] [Related]

  • 11. Identification and characterization of a lysophosphatidic acid receptor.
    Thomson FJ, Perkins L, Ahern D, Clark M.
    Mol Pharmacol; 1994 Apr 01; 45(4):718-23. PubMed ID: 8183251
    [Abstract] [Full Text] [Related]

  • 12. Lysophosphatidic acid is the unique platelet-activating substance in human malignant ascites.
    Sandmann G, Siess W, Essler M.
    Eur J Med Res; 2003 Sep 29; 8(9):397-404. PubMed ID: 14555295
    [Abstract] [Full Text] [Related]

  • 13. Synthesis of alpha-fluorinated phosphonates from alpha-fluorovinylphosphonates: a new route to analogues of lysophosphatidic acid.
    Xu Y, Qian L, Prestwich GD.
    Org Lett; 2003 Jun 26; 5(13):2267-70. PubMed ID: 12816425
    [Abstract] [Full Text] [Related]

  • 14. Neurotransmitter release from lysophosphatidic acid stimulated PC12 cells: involvement of lysophosphatidic acid receptors.
    Shiono S, Kawamoto K, Yoshida N, Kondo T, Inagami T.
    Biochem Biophys Res Commun; 1993 Jun 15; 193(2):667-73. PubMed ID: 8390248
    [Abstract] [Full Text] [Related]

  • 15. Lysophosphatidylethanolamine stimulates chemotactic migration and cellular invasion in SK-OV3 human ovarian cancer cells: involvement of pertussis toxin-sensitive G-protein coupled receptor.
    Park KS, Lee HY, Lee SY, Kim MK, Kim SD, Kim JM, Yun J, Im DS, Bae YS.
    FEBS Lett; 2007 Sep 18; 581(23):4411-6. PubMed ID: 17719584
    [Abstract] [Full Text] [Related]

  • 16. Phosphorothioate analogues of alkyl lysophosphatidic acid as LPA3 receptor-selective agonists.
    Qian L, Xu Y, Simper T, Jiang G, Aoki J, Umezu-Goto M, Arai H, Yu S, Mills GB, Tsukahara R, Makarova N, Fujiwara Y, Tigyi G, Prestwich GD.
    ChemMedChem; 2006 Mar 18; 1(3):376-83. PubMed ID: 16892372
    [Abstract] [Full Text] [Related]

  • 17. Concise synthesis of acyl migration-blocked 1,1-difluorinated analogues of lysophosphatidic acid.
    Xu Y, Prestwich GD.
    J Org Chem; 2002 Oct 04; 67(20):7158-61. PubMed ID: 12354017
    [Abstract] [Full Text] [Related]

  • 18. The emerging role of lysophosphatidic acid in cancer.
    Mills GB, Moolenaar WH.
    Nat Rev Cancer; 2003 Aug 04; 3(8):582-91. PubMed ID: 12894246
    [Abstract] [Full Text] [Related]

  • 19. Inhibition of lysophospholipase D activity by unsaturated lysophosphatidic acids or seed extracts containing 1-linoleoyl and 1-oleoyl lysophosphatidic acid.
    Liu XW, Sok DE, Yook HS, Sohn CB, Chung YJ, Kim MR.
    J Agric Food Chem; 2007 Oct 17; 55(21):8717-22. PubMed ID: 17887800
    [Abstract] [Full Text] [Related]

  • 20. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients.
    Xu Y, Gaudette DC, Boynton JD, Frankel A, Fang XJ, Sharma A, Hurteau J, Casey G, Goodbody A, Mellors A.
    Clin Cancer Res; 1995 Oct 17; 1(10):1223-32. PubMed ID: 9815916
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.